Treatment For Feline Leukemia (FeLV) And Immunodeficiency Virus (FIV) Receives License Renewal From USDA

T-Cyte Therapeutics, Inc. announced their conditional license renewal from the United States Department of Agriculture for Lymphocyte T-Cell Immunomodulator (LTCI). LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV). LTCI is licensed and distributed by IMULAN BioTherapeutics; a US based veterinary immunobiology company. Conditional licenses are granted by the USDA for products which have passed safety and purity testing and where there is an emergency need or no other product available. LTCI is undergoing additional efficacy and potency studies.

More from

• 'Tax changes could land your practice with someone else's bills', warns vet founder
• Pet Health Clubs' fight for survival remains unresolved
• How a teenage James Herriot moved from clinic to boardroom
• Frustration to innovation: The shaping of transformative hiring platform
• Animus launches SkinBond Multi for enhanced wound care